Early-Stage Drug Development Is Strategic Infrastructure. Can The US Afford To Lose It? So-Yeon KangandYunan Ji September 17, 2026

https://www.healthaffairs.org/content/forefront/early-stage-drug-development-strategic-infrastructure-can-us-afford-lose?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz-_8PeD8D7CeYXS2atyai1BegB3Sd9_5XCg5bmWh3PyMD7A6Xg2Ajqp1YOWprAzugexUtsjPz6t2OX_7D3msTAKgY_4eQQ&_hsmi=439651014&utm_source=hasu The globalization of biopharmaceutical innovation is likely to continue. The central challenge therefore is whether the US can use the heightened competition as a catalyst to strengthen its domestic ecosystem.